Last reviewed · How we verify

ORAL VORICONAZOLE and IV Amphotericin B

All India Institute of Medical Sciences · Phase 3 active Small molecule

ORAL VORICONAZOLE and IV Amphotericin B is a Antifungal agents (triazole and polyene) Small molecule drug developed by All India Institute of Medical Sciences. It is currently in Phase 3 development for Invasive aspergillosis, Candidemia and other Candida infections, Cryptococcal meningitis.

Voriconazole and amphotericin B are antifungal agents that disrupt fungal cell membrane integrity, while voriconazole inhibits ergosterol synthesis and amphotericin B binds directly to ergosterol causing cell lysis.

Voriconazole and amphotericin B are antifungal agents that disrupt fungal cell membrane integrity, while voriconazole inhibits ergosterol synthesis and amphotericin B binds directly to ergosterol causing cell lysis. Used for Invasive aspergillosis, Candidemia and other Candida infections, Cryptococcal meningitis.

At a glance

Generic nameORAL VORICONAZOLE and IV Amphotericin B
SponsorAll India Institute of Medical Sciences
Drug classAntifungal agents (triazole and polyene)
TargetFungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Voriconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, preventing ergosterol synthesis and destabilizing the fungal cell membrane. Amphotericin B is a polyene antibiotic that binds directly to ergosterol in the fungal cell membrane, creating pores that lead to cell leakage and death. The combination provides broad-spectrum antifungal coverage with complementary mechanisms of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ORAL VORICONAZOLE and IV Amphotericin B

What is ORAL VORICONAZOLE and IV Amphotericin B?

ORAL VORICONAZOLE and IV Amphotericin B is a Antifungal agents (triazole and polyene) drug developed by All India Institute of Medical Sciences, indicated for Invasive aspergillosis, Candidemia and other Candida infections, Cryptococcal meningitis.

How does ORAL VORICONAZOLE and IV Amphotericin B work?

Voriconazole and amphotericin B are antifungal agents that disrupt fungal cell membrane integrity, while voriconazole inhibits ergosterol synthesis and amphotericin B binds directly to ergosterol causing cell lysis.

What is ORAL VORICONAZOLE and IV Amphotericin B used for?

ORAL VORICONAZOLE and IV Amphotericin B is indicated for Invasive aspergillosis, Candidemia and other Candida infections, Cryptococcal meningitis, Serious fungal infections in immunocompromised patients.

Who makes ORAL VORICONAZOLE and IV Amphotericin B?

ORAL VORICONAZOLE and IV Amphotericin B is developed by All India Institute of Medical Sciences (see full All India Institute of Medical Sciences pipeline at /company/all-india-institute-of-medical-sciences).

What drug class is ORAL VORICONAZOLE and IV Amphotericin B in?

ORAL VORICONAZOLE and IV Amphotericin B belongs to the Antifungal agents (triazole and polyene) class. See all Antifungal agents (triazole and polyene) drugs at /class/antifungal-agents-triazole-and-polyene.

What development phase is ORAL VORICONAZOLE and IV Amphotericin B in?

ORAL VORICONAZOLE and IV Amphotericin B is in Phase 3.

What are the side effects of ORAL VORICONAZOLE and IV Amphotericin B?

Common side effects of ORAL VORICONAZOLE and IV Amphotericin B include Visual disturbances, Hepatotoxicity, Nephrotoxicity (amphotericin B), Hypokalemia, Infusion-related reactions, Photosensitivity.

What does ORAL VORICONAZOLE and IV Amphotericin B target?

ORAL VORICONAZOLE and IV Amphotericin B targets Fungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B) and is a Antifungal agents (triazole and polyene).

Related